皮下 versus 静脉帕博利珠单抗联合化疗治疗转移性非小细胞肺癌:III期3475A-D77试验
III期开放标签3475A-D77研究将初治IV期无EGFR/ALK/ROS1突变的转移性非小细胞肺癌患者按2:1随机分配至皮下帕博利珠单抗790 mg每6周或静脉帕博利珠单抗400 mg每6周联合铂双药化疗。皮下组第1周期AUC0-6周和稳态Ctrough的几何均值比非劣效于静脉组,客观缓解率两组相似,安全性一致。
要点
- 皮下帕博利珠单抗790 mg每6周联合化疗的药代暴露非劣效于静脉400 mg每6周。
- 皮下组中位注射时间2.0分钟(范围1-12分钟)。
- 两组客观缓解率分别为45.4%和42.1%,安全性特征一致。
核心结论
- 皮下帕博利珠单抗790 mg每6周联合化疗的总暴露和谷浓度非劣效于静脉帕博利珠单抗400 mg每6周,支持皮下制剂作为所有静脉帕博利珠单抗适应症的治疗选择。
研究设计与样本
- III期开放标签3475A-D77研究(NCT05722015),将初治IV期鳞状或非鳞状非小细胞肺癌且无EGFR、ALK或ROS1敏感突变的患者按2:1随机分配至皮下帕博利珠单抗790 mg每6周(n=251)或静脉帕博利珠单抗400 mg每6周(n=126),均联合铂双药化疗,共18周期。
主要发现
- 第1周期AUC0-6周几何均值比(96%CI)为1.14(1.06-1.22),P<0.0001;稳态Ctrough几何均值比(94%CI)为1.67(1.52-1.84),P<0.0001。
- 抗帕博利珠单抗抗体在皮下组检出率1.4%,静脉组0.9%。
- 皮下组 versus 静脉组客观缓解率分别为45.4% versus 42.1%(ORR比1.08,95%CI 0.85-1.37)。
- 其他疗效指标两组相似,安全性特征一致。
- 皮下组中位注射时间2.0分钟(范围1-12分钟)。
关键数值与推荐
- AUC0-6周和Ctrough几何均值比的非劣效界值为0.8。
- 第1周期AUC0-6周几何均值比1.14(96%CI 1.06-1.22),P<0.0001。
- 稳态Ctrough几何均值比1.67(94%CI 1.52-1.84),P<0.0001。
- 客观缓解率皮下组45.4% versus 静脉组42.1%(ORR比1.08,95%CI 0.85-1.37)。
临床怎么用
- 结果支持皮下帕博利珠单抗作为所有静脉帕博利珠单抗可用的适应症中的治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pembrolizumab with berahyaluronidase alfa is for subcutaneous (s.c.) administration. The phase III open-label 3475A-D77 study (NCT05722015) assessed s.c. pembrolizumab versus intravenous (i.v.) pembrolizumab, plus chemotherapy, for treatment of metastatic non-small-cell lung cancer (mNSCLC). PATIENTS AND METHODS: Participants with newly diagnosed stage IV squamous or nonsquamous NSCLC without sensitizing EGFR, ALK, or ROS1 alterations were randomized 2 : 1 to pembrolizumab s.c. 790 mg every 6 weeks (q6w) or pembrolizumab i.v. 400 mg q6w (18 cycles), each given with platinum-doublet chemotherapy. Dual primary endpoints were pharmacokinetic exposure measures of cycle 1 area under the curve (AUC0-6 weeks) and steady-state trough concentration (Ctrough) of pembrolizumab. The noninferiority margin for AUC0-6 weeks and Ctrough geometric mean ratios (GMRs) of pembrolizumab s.c. versus i.v. was specified as 0.8. Secondary endpoints included additional pharmacokinetic exposure measures, pembrolizumab immunogenicity, efficacy, and safety. RESULTS: In total 377 participants were randomized to the pembrolizumab s.c. (n = 251) or i.v. (n = 126) arms. The median time from randomization to data cut-off (12 July 2024) was 9.6 months (range 6.2-16.4 months). The median injection time for pembrolizumab s.c. was 2.0 min (range 1-12 min). The GMR [96% confidence interval (CI)] for cycle 1 AUC0-6 weeks was 1.14 (1.06-1.22); P < 0.0001. The GMR (94% CI) for steady-state Ctrough was 1.67 (1.52-1.84); P < 0.0001. Secondary pharmacokinetic endpoints were within established bounds for pembrolizumab. Anti-pembrolizumab antibodies were detected in 1.4% (pembrolizumab s.c. arm) and 0.9% (pembrolizumab i.v. arm) of participants. For the pembrolizumab s.c. versus i.v. arms, objective response rates (ORRs) were 45.4% versus 42.1% (ORR ratio 1.08, 95% CI 0.85-1.37). Other efficacy measures were similar and safety profiles were consistent between treatment arms. CONCLUSIONS: Overall exposure and trough concentrations of pembrolizumab s.c. 790 mg q6w were noninferior to those of pembrolizumab i.v. 400 mg q6w given with chemotherapy in participants with treatment-naive mNSCLC. Results support pembrolizumab s.c. as a treatment option in all indications where pembrolizumab i.v. can be used.
引用
- Felip E, Rojas CI, Schenker M, et al. Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial. Ann Oncol. 2025. PMID: 40157574. doi:10.1016/j.annonc.2025.03.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。